Skip to content

Effect van koolstof nanopartikels op ontsteking en stolling in de luchtwegen.

Effect of Carbon Nanoparticles on Inflammation and Coagulation after Bronchial Segmental Instillation. A dose escalation study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29149
Enrollment
24
Registered
2011-07-11
Start date
2011-09-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carbon nanoparticles - air pollution - lung inflammation - coagulation koolstof nanopartikels - luchtvervuiling - luchtwegontsteking - stolling

Interventions

Volunteers will receive a bronchial instillation of a carbon nanoparticle suspension. Controls will receive a bronchial instillation with saline.

Sponsors

Academic Medical Center (AMC) Amsterdam. Department of Pulmonology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy, male subjects between 18 and 45 years of age; 2. No clinically significant findings during physical examination and haematological and biochemical screening; 3. Baseline FEV1 > than 80% of predicted value; 4. Able to communicate well with the investigator and to comply with the requirements of the study; 5. Written informed consent; 6. No current smoking for at least 1 year and less than 5 pack years of smoking history.

Exclusion criteria

Exclusion criteria: 1. History of pulmonary or any other relevant disease; 2. History of enhanced bleeding tendency; 3. A history of smoking within the last 12 months, or regular consumption of greater than three units of alcohol per day; 4. Administration of any investigational drug within 30 days of study initiation; 5. Donation of blood within 60 days, or loss of greater than 400 ml of blood within 12 weeks of study initiation; 6. History of serious drug-related reactions, including hypersensitivity.

Design outcomes

Primary

MeasureTime frame
1. Total leukocyte count and differentials in bronchoalveolar lavage fluid; 2. Activation of coagulation and fibrinolysis in bronchoalveolar lavage fluid.

Secondary

MeasureTime frame
1. Amino acid pattern in exhaled breath condensate; 2. Metabolomic fingerprint as obtained by Liquid chromatography-mass spectrometry (LC-MS); 3. Safety outcome parameters (Physical complaints of the volunteer, Blood pressure, Heart rate, Temperature, Lungfunction, Oxygen saturation, (Serious) Adverse Events.

Contacts

Public ContactM. Berger
m.berger@amc.uva.nl+31 (0)20 566 8375

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)